Mazdutide MDT
GLP-1R · GCGR dual agonist
Oxyntomodulin-based dual GLP-1 and glucagon receptor agonist studied for effects on appetite, energy expenditure and glucose control.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- GLP-1R · GCGR dual agonist
- Category
- Metabolic & Incretin
- Type
- Single compound
- Abbreviation
- MDT
- Development and regulatory status
- Approved in China for chronic weight management (June 2025)
What researchers study
Mazdutide is a synthetic peptide, an oxyntomodulin-based dual agonist of the GLP-1 and glucagon receptors. It is studied for effects on appetite, energy expenditure and glucose control.
Research areas
- Dual GLP-1 and glucagon receptor agonism
- Energy expenditure and body-weight studies
- Glucose control and liver-fat research
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- phase 3 trial
In GLORY-1 (600+ adults in China), mean weight loss at 48 weeks was 12% and 14.8% in two dose groups versus 0.5% with placebo
- phase 3 trial
Weight loss of at least 15% occurred in 37% and 50.6% of participants in the two dose groups versus 2.1% with placebo
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- Survodutideanother GLP-1 and glucagon dual agonist for comparison
- Retatrutidetriple agonist that also includes glucagon-receptor activity
